Vaxcyte grants stock options to director Markels

Vaxcyte, Inc. director John Markels reported a compensatory grant of 23,029 stock options, each exercisable for one share of common stock at an exercise price of $56.04 per share.

Rhea-AI Filing Summary

Vaxcyte, Inc. director John Markels reported a compensatory grant of 23,029 stock options, each exercisable for one share of common stock at an exercise price of $56.04 per share. The options expire on July 16, 2036 and vest over 36 months: one-third vests on July 16, 2027, and the remaining portion vests in equal monthly installments thereafter, subject to his continuous service. Following this award, he holds 23,029 derivative securities directly.

Insider Trade Summary

Grant/Award: 23,029 shares

Grant/Award 1 txn

Insider Markels John

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	23,029	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 23,029 contracts (Direct)

Footnotes (1)

1. F1. Option shall vest over 36 months, 1/3 of which will vest on July 16, 2027 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.

Key Figures

Stock options granted: 23,029 options Exercise price: $56.04 per share Expiration date: July 16, 2036 +2 more

5 metrics

Stock options granted 23,029 options Grant of stock options to director John Markels

Exercise price $56.04 per share Exercise price for the stock options granted on July 16, 2026

Expiration date July 16, 2036 Expiration of the granted stock options

Total derivative securities after grant 23,029 options Director’s holdings following the reported transaction

Vesting period 36 months Options vest over 36 months, starting July 16, 2027

Key Terms

Stock Option (right to buy), exercise price, vesting, continuous service

4 terms

Stock Option (right to buy) financial

"security_title is listed as Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price is shown as 56.0400 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"Option shall vest over 36 months, 1/3 of which will vest on July 16, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service other

"subject to Reporting Person's continuous service to the Company"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity award did Vaxcyte (PCVX) director John Markels receive?

Director John Markels received a grant of 23,029 stock options in Vaxcyte, Inc. Each option is exercisable for one share of common stock at an exercise price of $56.04, with vesting over 36 months and expiration on July 16, 2036.

What is the exercise price of the new Vaxcyte (PCVX) stock options granted to John Markels?

The new stock options granted to John Markels have an exercise price of $56.04 per share. They are options to purchase Vaxcyte common stock, vesting over 36 months and expiring on July 16, 2036, subject to his continuous service with the company.

How do the Vaxcyte (PCVX) options granted to John Markels vest over time?

The options vest over 36 months: one-third of the grant vests on July 16, 2027, and 1/36 of the total vests monthly thereafter. All vesting is conditioned on John Markels’ continuous service to Vaxcyte through each vesting date.

When do the newly granted Vaxcyte (PCVX) stock options to John Markels expire?

The newly granted stock options to John Markels expire on July 16, 2036. After that date, any unexercised options become worthless. Until expiration, he may exercise vested options at the $56.04 exercise price, subject to plan and service conditions.

Is the Vaxcyte (PCVX) Form 4 for John Markels an open-market stock purchase?

No. The Form 4 reports a grant/award acquisition of stock options, not an open-market share purchase. Markels received 23,029 options at a $56.04 exercise price as compensation, with vesting tied to his ongoing service at Vaxcyte.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/16/2026 - 04:56 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Markels John

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, SUITE 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$56.04	07/16/2026		A		23,029		(1)	07/16/2036	Common Stock	23,029	$0	23,029	D

Explanation of Responses:

1. Option shall vest over 36 months, 1/3 of which will vest on July 16, 2027 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.

Remarks:

	John Markels, by /s/ Peter N. Efremenko, Attorney-In-Fact	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)